A Phase Three Study of the Safety and Immunogenicity of a Four-dose Series of 20-Valent Pneumococcal Conjugate Vaccine in Healthy Infants
Authors:
- Shelly SendersSSShelly Senders
- Nicola P. KleinNKNicola P. Klein
- Noor TamimiNTNoor Tamimi
- Allison ThompsonATAllison Thompson
- Gary BaugherGBGary Baugher
- James TrammelJTJames Trammel
- Yahong PengYPYahong Peng
- Peter GiardinaPGPeter Giardina
- Ingrid L. ScullyISIngrid L. Scully
- Michael PrideMPMichael Pride
- Kimberly J. CenterKCKimberly J. Center
- William C. GruberWGWilliam C. Gruber
Open Access
- 26 March 2024
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 43 (6) , 596-603
Abstract
Background: The 20-valent pneumococcal conjugate vaccine (PCV20) was developed to extend pneumococcal disease protection beyond 13-valent PCV (PCV13). Methods: This phase 3, double-blind study conducted in the United States/Puerto Rico evaluated PCV20 safety and immunogenicity. Healthy infants were randomized to receive a 4-dose series of PCV20 or PCV13 at 2, 4, 6 and 12–15 months old. Objectives included demonstrating noninferiority (NI) of PCV20 to PCV13 immunoglobulin G (IgG) geometric mean concentrations after doses 3 and 4 and percentages of participants with predefined IgG concentrations after dose 3, with 7 additional PCV20 serotypes compared with the lowest result among vaccine serotypes in the PCV13 group. Safety assessments included local reactions, systemic events, adverse events, serious adverse events and newly diagnosed chronic medical conditions. Results: Overall, 1991 participants were vaccinated (PCV20, n = 1001; PCV13, n = 990). For IgG geometric mean concentrations 1 month after both doses 3 and 4, all 20 serotypes met NI criteria (geometric mean ratio lower 2-sided 95% confidence interval > 0.5). For percentages of participants with predefined IgG concentrations after dose 3, NI (percentage differences lower 2-sided 95% confidence interval > –10%) was met for 8/13 matched serotypes and 6/7 additional serotypes; 4 serotypes missed the statistical NI criterion by small margins. PCV20 also elicited functional and boosting responses to all 20 serotypes. The safety profile of PCV20 was similar to PCV13. Conclusion: A 4-dose series of PVC20 was well tolerated and elicited robust serotype-specific immune responses expected to help protect infants and young children against pneumococcal disease due to the 20 vaccine serotypes. Clinical trial registration: NCT04382326.Keywords
This publication has 33 references indexed in Scilit:
- Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United StatesVaccine, 2022
- A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccinationVaccine, 2021
- A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of ageVaccine, 2021
- Ten year public health impact of 13-valent pneumococcal conjugate vaccination in infants: A modelling analysisVaccine, 2020
- Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adultsVaccine, 2019
- Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USAClinical Microbiology and Infection, 2016
- The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7AVaccine, 2011
- Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in GermanyVaccine, 2010
- Challenges in the evaluation and licensing of new pneumococcal vaccines, 7–8 July 2008, Ottawa, CanadaVaccine, 2009
- Safety and efficacy of the seven-valent pneumococcal conjugate vaccine: evidence from Northern CaliforniaEuropean Journal of Pediatrics, 2002